ReNeuron Reports New Positive Data Relating To CTX Stem Cell Platform

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said its CTX stem cell therapy candidate can be successfully re-programmed to a pluripotent state.

Pluripotent state is an embryonic stem cell-like state enabling differentiation into any cell type.

The therapeutics company said the CTX stem cell candidate is currently undergoing clinical evaluation for the treatment of stroke disability.

Looking forward, ReNeuron said it plans to develop new allogeneic cell lines, including NK and T-cells, that can "attack" cancer cells.

The company believes that CTX stem cell line could be used to produce new conditionally immortalised allogeneic cell lines from germ layers, including ectoderm, mesoderm and endoderm.

"The possibility of generating an allogeneic source of haematopoietic stem cells from our clinical-grade CTX cell line offers the prospect of a potential non-patient-specific alternative to those cancer immunotherapies in development that currently rely on the use of the patient's own T-cells," said Head of Research Randolph Corteling.

ReNeuron shares were trading 2.6% higher on Thursday at 60.00 pence each.